BIOSCIENCE NEUTRACEUTICALS, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-04-22: Form 8-K; Period of report 2019-03-21; Description 3.02 Unregistered Sales of Equity Securities; Details 3.02.
- 2019-02-07: Form 8-K; Period of report 2019-02-07; Description 8.01 Other Events; Details 8.01.
- 2018-12-12: Form 8-K; Period of report 2018-12-12; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events; Details 5.03.
- 2018-11-19: Form 8-K; Period of report 2018-11-14; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-04-22 | 8-K | 2019-03-21 | 3.02 Unregistered Sales of Equity Securities | 3.02 On March 21, 2019, our majority shareholder and our sole director, approved the issuance of 7,000,000 shares of common stock to Liang Chen, our Chief Executive Officer as compensation for management services provided to our company by Mr. Chen. | devv_8k.htm |
| 2019-02-07 | 8-K | 2019-02-07 | 8.01 Other Events | 8.01 Further to our Definitive Schedule 14C filed on January 18, 2019, a majority of our shareholders approved a reverse stock split on a basis of 40 old shares for one (1) new share of our issued and outstanding common stock. | devv_8k.htm |
| 2018-12-12 | 8-K | 2018-12-12 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 As previously disclosed in our Current Report on Form 8-K filed on November 19, 2018, on November 14, 2018, our board of directors approved an agreement and plan of merger to merge with our wholly-owned subsidiary, Bioscience Neutraceuticals, Inc. a Nevada corporation, to effect a name change from JobLocationMap, Inc. to Bioscience Neutraceuticals, Inc. Our company will remain the surviving entity. | jbct_8k.htm |
| 2018-11-19 | 8-K | 2018-11-14 | 8.01 Other Events | 8.01 On November 14, 2018, our board of directors approved an agreement and plan of merger to merge with our wholly-owned subsidiary, Bioscience Neutraceuticals, Inc. a Nevada corporation, to effect a name change from JobLocationMap, Inc. to Bioscience Neutraceuticals, Inc. Our company will remain the surviving entity. | jbct_10q.htm |
| 2017-12-05 | 8-K | 2017-11-30 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 As previously disclosed on Form 8-K, on October 2, 2017, Joblocationmap Inc. (the “Company”) completed a share exchange transaction (the “Reverse Merger”) in which the Company issued shares of its common stock to the stockholders of Bio Health Products Inc. (“BHP”), in exchange for all of the issued and outstanding shares of common stock of BHP. | jbct_8k.htm |
| 2017-11-09 | 8-K | 2017-07-10 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 5.06 Change in Shell Company Status | 1.01 The disclosures set forth under Item 2 are incorporated by reference into this Item 1. 2.01 On July 10, 2017, the Company acquired all of the shares of Bio Health Products Inc. a Nevada corporation, in exchange for 200,000 shares of the Company’s common stock, whereby Bio Health Products became a wholly owned subsidiary of the Company. 5.06 Prior to the closing of the Sale and Purchase Agreement, we were a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). | jbct_8k.htm |
| 2017-05-17 | 8-K | 2017-04-27 | 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.01 As of April 27, 2017, Omri Morchi and Eden Shoua (the “Sellers”), entered into a Common Stock Purchase Agreement (the “Stock Purchase Agreement”) pursuant to which the Sellers agreed to sell to Peak Global Consultants Limited (the “Purchaser”), the 8,000,000 shares of common stock of the Company (the “Shares”) owned by the Sellers, constituting approximately 84.2% of the Company’s 9,500,000 issued and outstanding common shares, for $235,000. 5.02 Pursuant to the terms of the Stock Purchase Agreement, the Sellers resigned their positions, effective May 12, 2017. | jbct_8k.htm |
| 2017-05-15 | 8-K | 2017-05-04 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On May 4, 2017, Weinberg & Baer, LLC (the “Former Accountant”) declined to stand for re-election due to public company partner rotation requirements. | jbct_8k.htm |